Stocks · News reference
VolitionRx Limited has executed a non-binding Letter of Intent with Missionpharma A/S to explore the development and distribution of its prototype Lateral Flow Technology for NETosis.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
VolitionRx Limited has made a $500,000 cash prepayment toward the outstanding principal balance of its senior secured convertible promissory note held by Lind Global Asset Management XII LLC.
Filed: 2026-10-27 AccNo: 0001477932-26-006470 Size: 178 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of SepsisHENDERSON, Nev., Sept. 17,